What You'll Learn
Table of Contents
Why This Is A Real Question, Not Just A Worry
The menopause transition changes body composition independently of anything else. Fat redistributes toward the abdomen, and lean mass begins to decline — one of the papers below puts that decline at up to 0.5% during the transition itself, before any deliberate weight loss.
So the question is not vanity. If a woman is already losing lean tissue because of where she is in life, and then adds a medication that produces rapid weight loss, the two effects arrive at the same target.
That is the thing worth knowing. Not whether the drug works — whether what it takes off is different.
Legion Whey+
This page names 1.2-1.6 g/kg and resistance training as the two levers. The protein half is the one that fails first when appetite drops.
Check price at Legion →Disclosure: we earn a commission if you buy through this link, at no extra cost to you. It does not change what this page says. Supplements do not treat or replace a GLP-1 medication, and nothing here is medical advice.
Does It Work The Same After Menopause?
One study looked directly at that, comparing postmenopausal and premenopausal women on the same protocol.
Postmenopausal women started heavier (95 kg versus 86.4) and with more fat mass, but after four months on semaglutide 1 mg the results were statistically indistinguishable: 5.8% versus 5.1% of body weight lost (p = 0.4). Fat mass lost was also comparable (4.1 versus 3.1 kg, p = 0.3).
Read the study on PubMed ↗Bottom line: The short answer to the common worry: on the available data, menopause does not appear to blunt how much weight comes off. It is not a reason to expect less.
The Finding Almost Nobody Reports
A separate cohort asked a narrower question: among postmenopausal women on semaglutide, does it matter whether they are also on menopause hormone therapy?
Total body weight loss was higher in the hormone therapy group at every measurement: 7% versus 5% at three months (p = 0.01), 13% versus 9% at six, 15% versus 10% at nine, and 16% versus 12% at twelve (p = 0.04). The association held after adjusting for confounders, and a greater share of the hormone therapy group reached both the 5% and 10% thresholds.
Read the study on PubMed ↗Now Read It Properly: Sixteen Women
A four-point gap at twelve months is a striking headline. Here is what sits underneath it.
The hormone therapy group was sixteen people. The comparison group was ninety. A difference measured across sixteen individuals is fragile in a way a percentage does not communicate — a handful of unusual responders moves the average substantially.
It was retrospective, not randomised. Nobody was assigned to hormone therapy for the purposes of this study. The women taking it chose to, or were prescribed it, for their own reasons — and the kind of person who is on hormone therapy may differ from the kind who is not in ways no adjustment fully captures.
The authors say so themselves. Their conclusion ends with a call for larger studies to confirm the result. That is not a formality; it is the correct reading of their own data.
So: a real signal, from a small group, that has not yet been tested properly. Interesting enough to raise with a clinician who already knows your history. Not a reason to start a hormone therapy you were not otherwise considering.
Important: Menopause hormone therapy is a clinical decision with its own risks and benefits, weighed against personal and family history. It is not a weight-loss intervention, and nothing on this page should be read as suggesting it be started or stopped for that reason.
The Part That Actually Differs
Buried in the comparison study is the number this site cares about most.
Lean mass change over four months was −0.4 kg in the postmenopausal group against −1.1 kg in the premenopausal one (p = 0.1). Not statistically significant, and the direction is the opposite of what most people assume — the postmenopausal women lost less lean tissue, not more.
Do not over-read that. p = 0.1 in a small sample means the study could not tell the two apart, which is different from showing they are the same. And four months is short.
What it does undercut is the assumption that being postmenopausal makes muscle loss on these medications inevitably worse. On this data, it does not.
What remains true regardless is the baseline: lean mass is already declining through the transition. Our sarcopenia guide covers why that starting point matters more than the rate of loss during any single intervention.
What To Actually Do With This
Three things the evidence supports, and one it does not.
Expect it to work. Menopause is not a reason to anticipate a worse result. On the available comparison, the weight came off the same.
Protect the lean tissue anyway. Not because menopause makes it worse — the data does not show that — but because the starting point is lower. Protein at 1.2–1.6 g/kg and resistance training are the levers, and they are the same levers at any age.
Mention hormone therapy if it is already on the table. If you are discussing it with a clinician for menopausal symptoms, this cohort is worth them knowing about. It is one more data point in a decision that has several.
What the evidence does not support: starting hormone therapy in order to lose more weight. Sixteen women in a retrospective cohort is not the basis for that, and the authors would be the first to say so.
